Abstract
Mycobacterium w is a non-pathogenic, saprophytic, atypical mycobacterium with the ability to produce macrophage activating factors from lymphocytes of human patients. Prior immunization with heat-killed suspension of Mycobacterium w shows protection against sub-lethal infection with Mycobacterium tuberculosis H37Rv in mice. Heatkilled Mycobacterium w vaccine is manufactured by M/s Cadila Pharmaceuticals, Ahmedabad, India. Combined heatkilled M. w vaccine and multidrug treatment (MDT) revealed clinical, histological and bacteriological improvements in highly bacillated untreated anergic lepromatous cases of leprosy. In healthy contacts of leprosy patients, M. w vaccine has shown lepromin conversion and protection against leprosy. Only a few clinical studies have been carried out using antituberculous treatment with and without M. w vaccine in pulmonary tuberculosis, in which faster sputum conversion and higher cure rate have been observed in M. w group. M. w vaccine has shown potential of Tuberculin conversion in HIV positive subjects. In a study, five monthly doses of M. w vaccine have shown highly significant increase in CD4 count in HIV positive human beings. More clinical trials are needed to confirm beneficial role of M. w vaccine as an immunomodulator in therapy and prevention of tuberculosis, particularly so in multidrug resistant tuberculosis and those with HIV infection.
Keywords: Mycobacterium w, immunomodulator, tuberculosis, leprosy, immunoprophylaxis, immunotherapy
Current Respiratory Medicine Reviews
Title: Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis
Volume: 2 Issue: 2
Author(s): Murli L. Mathur
Affiliation:
Keywords: Mycobacterium w, immunomodulator, tuberculosis, leprosy, immunoprophylaxis, immunotherapy
Abstract: Mycobacterium w is a non-pathogenic, saprophytic, atypical mycobacterium with the ability to produce macrophage activating factors from lymphocytes of human patients. Prior immunization with heat-killed suspension of Mycobacterium w shows protection against sub-lethal infection with Mycobacterium tuberculosis H37Rv in mice. Heatkilled Mycobacterium w vaccine is manufactured by M/s Cadila Pharmaceuticals, Ahmedabad, India. Combined heatkilled M. w vaccine and multidrug treatment (MDT) revealed clinical, histological and bacteriological improvements in highly bacillated untreated anergic lepromatous cases of leprosy. In healthy contacts of leprosy patients, M. w vaccine has shown lepromin conversion and protection against leprosy. Only a few clinical studies have been carried out using antituberculous treatment with and without M. w vaccine in pulmonary tuberculosis, in which faster sputum conversion and higher cure rate have been observed in M. w group. M. w vaccine has shown potential of Tuberculin conversion in HIV positive subjects. In a study, five monthly doses of M. w vaccine have shown highly significant increase in CD4 count in HIV positive human beings. More clinical trials are needed to confirm beneficial role of M. w vaccine as an immunomodulator in therapy and prevention of tuberculosis, particularly so in multidrug resistant tuberculosis and those with HIV infection.
Export Options
About this article
Cite this article as:
Mathur L. Murli, Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis, Current Respiratory Medicine Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339806776843120
DOI https://dx.doi.org/10.2174/157339806776843120 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry Strain Typing of Mycoplasma pneumoniae and its Value in Epidemiology
Current Pediatric Reviews Tuberculosis Treated by Multiple Drugs: An Overview
Current Drug Delivery Preface: The Inaugural Issue of Clinical Immunology Endocrine Metabolic Drugs
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Computational Simulations of the Immune System for Personalized Medicine: State of the Art and Challenges
Current Pharmacogenomics and Personalized Medicine TB Diagnostics – Old and New
Current Respiratory Medicine Reviews Implication on the Function of Novel Xn-relE Toxin Structure of Xenorhabdus nematophila Using Homology Modeling
Current Bioinformatics 1,2,4-Oxadiazoles Identified by Virtual Screening and their Non-Covalent Inhibition of the Human 20S Proteasome
Current Medicinal Chemistry Toward Integrase Defective Lentiviral Vectors for Genetic Immunization
Current HIV Research PASTA in Penicillin Binding Proteins and Serine/Threonine Kinases: A Recipe of Structural, Dynamic and Binding Properties
Current Medicinal Chemistry Antimicrobial Activities of Synthetic Arylidine Nicotinic and Isonicotinic Hydrazones
Letters in Drug Design & Discovery SCYPPred: A Web-Based Predictor of SNPs for Human Cytochrome P450
Protein & Peptide Letters Editorial (Thematic Issue: Current Tendencies in Antimicrobial Research: Medicinal Chemistry of Antibacterial Agents and Advances in the Use of Computational Methodologies)
Current Topics in Medicinal Chemistry Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Effect of Pistacia atlantica on the Elimination of Helicobacter pylori and Improvement of Gastric Reflux in Patients with Chronic Cough: A Randomized Clinical Trial
Current Traditional Medicine Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Mode of Action of Anti-Infective Agents Focus on Oxidative Stress and Electron Transfer
Current Pharmaceutical Design Synthesis, Antitubercular Activity, Molecular Modeling and Docking Studies of Novel Thiazolidin-4-One Linked Dinitrobenzamide Derivatives
Current Bioactive Compounds